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Abstract 
Nanotechnology and bioengineering have converged over the past decades, by which the application of multi‑
functional nanoparticles (NPs) has been emerged in clinical and biomedical fields. The NPs primed to detect disease‑
specific biomarkers or to deliver biopharmaceutical compounds have beena validated in conventional in vitro culture 
models including two dimensional (2D) cell cultures or 3D organoid models. However, a lack of experimental models 
that have strong human physiological relevance has hampered accurate validation of the safety and functionality of 
NPs. Alternatively, biomimetic human “Organs‑on‑Chips” microphysiological systems have recapitulated the mechani‑
cally dynamic 3D tissue interface of human organ microenvironment, in which the transport, cytotoxicity, biocom‑
patibility, and therapeutic efficacy of NPs and their conjugates may be more accurately validated. Finally, integration 
of NP‑guided diagnostic detection and targeted nanotherapeutics in conjunction with human organs‑on‑chips can 
provide a novel avenue to accelerate the NP‑based drug development process as well as the rapid detection of cel‑
lular secretomes associated with pathophysiological processes.
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1 Introduction
Nanoparticles (NPs) have been extensively applied to 
biomedical fields. For example, gold NPs have specific 
optical properties and surface plasmon resonance (SPR) 
effect, which enable to rapidly and accurately detect bio-
markers in combination with immunoselective molecules 
such as antibodies [1]. NPs perform as a therapeutic 
adjuvant with multiple functionality, by which pro-
grammed drug delivery as well as enhanced therapeutic 
efficacy can be expected [2]. Despite of these advantages, 
there are evident challenges in terms of the safety assess-
ment of NPs in the human body [3, 4]. For instance, only 
a limited number of nanotherapeutics using albumin 
NPs [5] or iron oxide NPs [6] has been approved by the 
US Food and Drug Administration (FDA) because of the 
unclear pharmacokinetics (PK) of NPs in terms of the 
nanotoxicity and absorption, distribution, metabolism, 
and excretion (ADME) profiles [5]. To validate PK pro-
files of NPs, animal models (mostly rodent surrogates) 
have been widely exploited [7]. Indeed, the potential of 
animal models for testing NPs has been validated in a 
variety of biomedical researches such as diagnostics and 
therapeutics [2, 8–10], delivery of drugs or genes [11–13] 
and imaging for a target organ or transplanted cells [14, 
15]. Furthermore, animal models have provided valu-
able in vivo rationales to ultimately target human, such as 
image-guided surgery using near infrared (NIR) emitting 
dye-loaded NPs [16], NP-based tracking of transplanted 
stem cells under magnetic resonance imaging (MRI) or 
fluorescence imaging [15], and cancer treatment using 
anti-cancer drug-conjugated NPs [17]. Although ani-
mal models are useful to track the translocation of NPs 
in  vivo, it is notably challenging to understand cellular 
and molecular mechanism of NPs in a spatiotemporal 
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manner. Moreover, the discrepancy in physiological 
responses between animal models and human may result 
in serious misunderstanding of the efficacy and nanotox-
icity of NPs.
Alternatively, microfluidic models in part allow in vivo 
relevant culture of human cells under physiological fluid 
shear stresses mimicking either the blood circulation 
or the interstitial extracellular fluid that may influence 
on the transport of NPs [18, 19]. In recent years, break-
throughs of microfluidic approaches in combination 
with multi-cellular co-culture have emerged biomimetic 
human “Organs-on-Chips” microphysiological system 
that can recapitulate the in vivo relevant physiology and 
pathology in  vitro [20]. The microengineered human 
organ models have leveraged the “Reverse Engineering” 
approach to demonstrate organ-level responses of highly 
organized tissue surrogate reconstituted in a structur-
ally defined 3D microfluidic device under organ-specific 
mechanical actuations [21]. In this bioinspired organo-
mimetic model, multiple types of tissue-specific human 
cells including differentiated epithelium, capillary or 
lymphatic endothelium, mesenchymal connective tis-
sues, tissue-resident or circulating immune cells, as well 
as living human microbiome can be contemplated to 
cogently validate the efficacy and toxicity of NP-based 
nanotherapeutics.
In this review, we discuss recent progresses of NP-
guided diagnostics and therapeutics that have been 
applied to the in vitro models. In particular, we focus on 
the potential applications of NPs in human organs-on-
chips microsystems to assess the functional reactivity 
and the detection capacity of NPs that can be translated 
to applicability in clinical diagnostics and therapeutics.
2  In vitro models for validating the functionality 
of NPs
2.1  Application of the NPs in the biomedical field
NPs are materials with a size that range between 1 and 
1000  nm. NPs have been applied in chemical, physical, 
biological, environmental, pharmaceutical, biomedical, 
and clinical fields based upon the physicochemical and 
photonic properties [7, 22]. NPs have strong reactive 
nature in chemical and biological reactions due to the 
high surface-to-volume ratio [23], which enables ver-
satile applicability in in  vivo imaging and clinical thera-
peutics. Inorganic NPs made of gold or magnetics have 
been used for the SPR effects [1] or magnetic resonance 
[24], respectively. Organic NPs such as biodegradable 
polymeric NPs [25] or liposomes [26] have been used for 
drug encapsulation. It is technically straightforward to 
conjugate biological or chemical drugs with diverse func-
tional moieties displayed on the NPs [27]. For example, 
monoclonal antibodies (mAb) can be conjugated to the 
surface of NPs to detect specific biomarkers or receptors 
expressed on the cell surface. Various fluorescent mate-
rials such as fluorescein isothiocyanate (FITC) or green 
fluorescent protein (GFP) have been employed to encap-
sulate the NPs for imaging purpose [28].
NPs have several advantages for the applications of 
in  vivo diagnostics, imaging, and therapeutic treatment 
[2]. NPs can be leveraged for the targeted delivery to the 
tumor region for localized distribution and facilitated 
cellular uptake. NPs can specifically navigate to tumor 
cells in a passive or an active way (Fig. 1a) [29]. Intrave-
nously injected NPs are passively delivered to the tumor 
region, where the surrounding neovascularized blood 
vessels have abundant proliferating endothelial cells, 
deficient pericytes, and aberrant basement membrane 
formation, which leads to the increased vascular perme-
ability [30]. Moreover, lymph vessels around the tumors 
do not efficiently function to drain body fluid from the 
tumor region. Thus, the NPs loaded with drugs present 
an enhanced permeability and retention (EPR) effect of 
the drugs during the delivery through the vascular sys-
tem [30]. NPs conjugated with aptamers or antibodies 
can specifically bind to the receptors on the surface of 
cancer cells such as vascular endothelial growth factor 
receptor (VEGFR), a key mediator of angiogenesis [31]. 
Since the healthy non-cancerous cells have significantly 
less expression of VEGFR, the aptamer-conjugated NPs 
penetrate through the cancer cells more efficiently via 
receptor-mediated endocytosis. NPs can be also used as a 
delivery carrier of drug compounds with enhanced stabil-
ity [32], by which the controlled release of carried drugs 
triggered by pH, temperature, or enzymatic reactions is 
possible to the target site [33]. For example, pH-sensitive 
magnetic nano-complex composed of iron oxide NPs and 
pH-responsive ligand demonstrates effective diagnosis 
and therapy against colorectal cancer. By targeting the 
acidic tumor microenvironment, pH-responsive NPs can 
generate singlet oxygen in the tumor, which induces pho-
todynamic therapeutic reactions to selectively kill can-
cer cells (Fig.  1b) [34]. NPs can also have photothermal 
effects in combination with therapeutic effects of embed-
ded drugs [35, 36], which synergistically boosts up the 
efficacy of clinical interventions.
2.2  Static 2D cell culture models
Existing 2D cell culture models are mostly static, simple, 
and straightforward to carry out the assessment of the 
cytotoxicity of NPs. After treating various cell lines with 
NPs for 2–72  h, trypan blue assay, fluorescence-based 
viability assay using a mixture of Calcein AM (live) and 
ethidium homodimer-1 (dead), lactate dehydrogenase 
(LDH) assay, or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay have been abundantly 
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applied to test the cytotoxicity of NPs [37, 38]. For exam-
ple, permeability and cytotoxicity of NPs are analyzed 
using a polarized human intestinal epithelial Caco-2 
monolayer grown on the Transwell [39]. In this study, 
three different sizes of gold NPs (15, 50 and 100  nm in 
diameter) are applied, in which the transport of NPs 
through a Caco-2 monolayer is measured via inductively 
coupled plasma mass spectroscopy (ICP-MS) (Fig.  1c). 
NPs with 50 nm in diameter show the highest apparent 
permeability for various time periods (up to 24  h). This 
study reveals that the size of NPs may influence on the 
absorption, accumulation, and nanotoxicity of NPs to the 
intestinal epithelium. However, the 2D cell culture mod-
els are too simple to emulate the complex in vivo human 
microenvironment because available cell lines often 
poorly differentiate [40]. Furthermore, a lack of physi-
cal dynamic motions and fluid flow in cell-based surro-
gates may produce considerable discrepancy with in vivo 
responses.
2.3  Static 3D cell culture models
Recently highlighted 3D organoid culture models have 
provided improved physiological cell morphology with 
self-organized microarchitecture [41], by which some 
organoid models have been utilized for demonstrating 
the infection of pathogenic bacteria [42] or viruses [43]. 
However, the nature of organoid cultures that requires 
heavy extracellular matrix (ECM) may hamper the effec-
tive application of NPs. For instance, organoid microen-
vironment can alter the result of cytotoxicity [44], where 
Fig. 1 Therapeutic applications of NPs. a Mechanism of the transport of NPs to the tumor lesion through blood vessels. NPs escape reticuloen‑
dothelial system (RES) and reach to the targeted tumor cells. NPs present enhanced permeability and retention (EPR) during the delivery through 
the vascular system. The targeting ligand‑modified NPs can specifically bind to the receptors on the surface of cancer cells. Reproduced with 
permission [29]. Copyright 2014, Elsevier. b Multifunctional pH‑sensitive NPs consists of 3 nm iron oxide NPs (average diameter, ~70 nm) and 
pH‑responsive ligand induce charge repulsion in pH below 6.5. NPs‑guided photodynamic therapy is demonstrated to the human colon cancer 
(HCT116) cells by displaying magnetic resonance imaging after laser irradiation. A graph shows that the pH sensitive NP‑therapeutics successfully 
inhibit the growth of tumor. Reproduced with permission [34]. Copyright 2014, American Chemical Society. c Internalization of the gold NPs (50 nm 
in diameter) into intestinal Caco‑2 epithelial cells. After 2 h of treatment, gold NPs indicated by red circles penetrate through the microvilli on the 
apical brush border (a white dotted oval circle) of Caco‑2 cells. An arrow indicates the direction of cellular uptake from apical to basolateral side 
across microvilli. Scale bar 500 nm. Reproduced with permission [39]. Copyright 2015, American Chemical Society
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the ECM holding organoid bodies hinders the penetra-
tion of NPs into the human hepatic (HepaRG) cells 
because of the dense accumulation of NPs in the ECM 
[45] limits NP-cell interactions [46]. A recent study 
demonstrates that the penetration of polyethylenimine 
(PEI)-coated superparamagnetic NPs containing siRNA 
into 3D fibroblast (NIH-3T3) organoids is much slower 
than that of NPs into 2D cultures of the same cells, sug-
gesting that the 3D microstructure of organoids better 
mimic the in vivo circumstance during the test of NP-
guided siRNA gene silencing [47]. The neuroblastoma 
(SH-SY5Y) organoids models are also used to assess the 
chemotherapeutic efficacy of doxorubicin in conjuga-
tion with the NPs synthesized by the borate-containing 
chitosan (monomer, N-3-acrylamidophenylboronic 
acid) [48]. Interestingly, the iRGD (internalizing l-argi-
nine, glycine and l-aspartic acid)-conjugated NPs shows 
significantly improved penetration and the chemo-
therapeutic efficiency on the multicellular organoids 
compared to doxorubicin alone or non-conjugated NPs 
alone. A prostate cancer organoid model using the pros-
tate adenocarcinoma line (LNCaP cells) also confirms 
that the uptake of doxorubicin-loaded NPs induces 
apoptotic responses [49]. Furthermore, this model also 
reveals that the engineered organoids demonstrate a 
higher level of multidrug resistance (MDR) proteins 
such as multidrug resistance protein 1 (MRP1) and lung 
resistance-related protein (LRP), which are generally 
overexpressed in tumor cells due to their hypoxic condi-
tion, low nutrients supply, or low pH. In this study, 3D 
organoid models show significantly (p < 0.05) increased 
level of MDR compared to that obtained in the 2D cul-
tures, suggesting that the tumor organoid models may 
be useful to better predict the therapeutic responses of 
NP-conjugated drugs in the presence of MDR effects. 
However, 3D organoid models still need further opti-
mizations such as the size and density of cell aggregates 
and the treatment period of NPs as well as drug-conju-
gated NPs [50].
The NPs conjugated with poly-thymine DNA are also 
exploited for the targeted delivery using the intestinal 
organoids as an intervention against inflammatory bowel 
disease (IBD) [51] (Fig. 2a). The key idea in this study is 
to utilize the mouse primary intestinal stem cell (ISC)-
derived intestinal organoids containing the DNA-con-
jugated gold NPs as a delivery vehicle (named “Trojan 
horse system”) to inject back into the host body, by which 
the negatively charged DNA-Au NPs intervene the posi-
tively charged proteins such as transferrin prevalently 
found in the inflamed intestine in IBD patients [52]. 
Using this model, improved distribution, local drug con-
centration, and therapeutic efficacy are expected; how-
ever possible attack of immune system when using the 
donor cells implanted to the recipients should be further 
considered.
2.4  Microfluidic cell culture models
Microfluidics technology has provided a controllable 
microenvironment in micro-scale channels, in which 
human cells, predominantly epithelium or endothelium, 
can robustly and reproducibly grow under trickling slow 
flow of culture medium [53]. In this simple laminar flow 
regime, cells growing in the microchannel can commu-
nicate with each other via diffusion [54]. Microfluidic 
approach is valuable to assess the permeability of NPs 
into the neovascularized region in the tumor, by which 
the fluidic nature in the device mimics the in  vivo vas-
culature with fluid shear stress [55]. Endothelial per-
meability of NPs has been used to validate the effective 
delivery of NPs to the tumor tissue. Since the vascular 
walls nearby the cancer lesion have nano-sized gaps, 
where tumor endothelial cells have ruffled margins 
and fragile cytoplasmic projections creating openings 
or small intercellular gaps in the vessel wall [56], an 
endothelial monolayer in this region is more permeable 
than that in healthy sites. Inspired by this observation, a 
microfluidic system lined by endothelium has been uti-
lized to test the transport of NPs that more closely mimic 
the fluidic nature [57]. To evaluate the vascular perme-
ability of NPs, human umbilical vein endothelial cells 
(HUVEC) have been widely used to test various NPs 
such as mesoporous silica NPs, gold NPs, quantum dots, 
and liposomes [58–62]. For the effective delivery of NPs 
to the endothelial cells, intercellular adhesion molecule 
1 (ICAM-1) can be targeted [59], where the delivery of 
NPs onto the endothelial cell surface can be different in 
static versus microfluidic conditions (Fig.  2b) [63]. The 
NPs conjugated with anti-ICAM-1 antibody are less 
internalized into the endothelium under flow (Fig.  2b, 
“Flow”) compared to the cells cultured in the same con-
dition but under static condition (Fig. 2b, “Static”), sug-
gesting that the fluid flow-mediated shear stress may 
regulate the endothelial endocytosis of the delivery of 
NPs, partially because the reorganization of actin stress 
fibers under fluidic conditions may interfere the uptake 
of anti-ICAM-1-NPs.
For the toxicological test of NPs, the shear stress dur-
ing physiological flow is also an important factor in terms 
of toxicity evaluation towards human cells. A microflu-
idic system employing an endothelial layer mimics the 
blood vessel [58], where introduction of gold NPs into 
the microfluidic channel lined by an endothelial mon-
olayer of HUVEC shows significantly reduced cytotox-
icity (p  <  0.05) of HUVEC cells under the physiological 
flow at 5  µL/min (corresponding shear stress, 0.1 dyne/
cm2) for 48  h compared to the toxicity level measured 
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in a static 24-multiwell plate. Another study demon-
strates how the defined physiological flow (shear stress, 
10 dyne/cm2) emulating the microenvironment of lung 
alveolar vasculature influences the cytotoxicity of the dif-
ferent type of NPs on the human lung alveolar epithelial 
cells (A549 line) and mouse embryonic fibroblast (NIH-
3T3 line) (Fig. 2c) [19]. Briefly, when the lung epithelial 
A549 cells are exposed to the zinc oxide (ZnO) NPs in 
either static or fluidic condition, the cellular toxicity in 
response to the fluidic versus static conditions is distinct 
with a statistical significance (p  <  0.05) (Fig.  2c, “ZnO-
NP”). However, cells exposed to titanium dioxide (TiO2) 
NPs do not significantly respond to TiO2 NPs nor to the 
hydrostatic conditions regardless of the concentration of 
NPs (Fig. 2c, “TiO2-NP”), suggesting that the reactivity of 
NPs in response to the applied shear stress can be differ-
ent from the material of NPs.
In addition, photosensitizer (IR-780)-encapsulated NPs 
are investigated for the efficient delivery and therapeutic 
efficacy of NP to human lung cancer cells under micro-
fluidic condition [64]. Human lung alveolar epithelial 
A549 line and normal lung fibroblast cell line (MRC-5) 
cultured in each PDMS/glass hybrid channel are used 
to quantitate the efficiency of cellular internalization 
of NPs at different sizes and surface properties. After 
the IR-780-NPs are introduced to both cancer and non-
cancerous cells, energy from light-emitting diode (LED) 
is irradiated. The cellular uptake of NPs conjugated with 
IR-780 is significantly higher in the A549 cancer cells 
than in the MRC-5 normal lung cells, suggesting that the 
synthesized NPs can be used as a potential delivery sys-
tem for hydrophobic photosensitizers to target the lung 
carcinoma.
As discussed, application of NPs in the microfluidic 
system is a promising way to validate the functionality of 
NPs in tunable and scalable controls. The conventional 
microfluidic approaches are robust and straightfor-
ward, and can easily be utilized to build a single micro-
channel with various geometric patterns [53]. However, 
these models mostly rely on controlling the microflu-
idic regimes without other microenvironmental fac-
tors such as mechanical deformations or 3D transmural 
Fig. 2 Reactivity of NPs under physiological fluidic conditions. a A “Trojan horse” delivery of Au‑NPs conjugated with poly‑thymine encapsulated 
inside the mouse intestinal stem cell‑derived organoids. Reproduced with permission [51]. Copyright 2015, Royal Society of Chemistry. b Effect of 
shear stress on the uptake of anti‑ICAM‑1/NPs by endothelial cells experienced with static (i.e. no flow) or fluidic condition (shear stress, 4 dyne/cm2) 
at 37 °C for 2 h with TNF‑α‑containing culture medium. Arrows indicate the internalized FITC‑labeled anti‑ICAM‑1/NPs (green) in the HUVEC. Arrow-
heads show the non‑internalized anti‑ICAM‑1/NPs (red). A graph shows the quantification of internalized anti‑ICAM‑1/NPs under static versus fluidic 
conditions. Scale bar 10 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Reproduced with permission [63]. Copyright 2011, Elsevier. c Toxicity test of ZnO and 
TiO2 NPs against lung cancer A549 cells in static and fluidic conditions (10 dyne/cm
2). *p < 0.05. Reproduced with permission [19]. Copyright 2015, 
Springer
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tissue–tissue interface [65, 66]. Next section, we discuss 
how these limitations in conventional microfluidic mod-
els are improved in human organs-on-chips models to 
assess the functionality of NPs.
2.5  Microengineered human organs‑on‑chips models
The human organs-on-chips are recently emerged micro-
physiological systems that are leveraging microfluidic 
technology. Organs-on-chips models primarily focus on 
the reconstitution of 3D microstructure and tissue–tissue 
interface of a human organ, by which they recapitulate 
organ-level functions related with homeostasis or patho-
physiological responses. Application of organs-on-chips 
models have dramatically increased in drug screening 
and delivery [67]. In particular, new microphysiological 
models of human organs have emulated physiological 
functions of the breathing motions in the lung [65], host-
microbe ecosystem and peristalsis-like mechanics in the 
gut [66, 68], blood cleansing functions in the spleen [69, 
70], reabsorption and transport in the kidney [71, 72], 
microvascular networks and blood perfusion [73], or 
blood–brain-barrier in the brain [74, 75] that can be used 
to potentially validate the efficacy, targeted delivery, PK/
PD profiles, functionality, and toxicity of NPs [65, 67]. 
While the potential of converging the NPs with organs-
on-chips microsystems is enormous, applications of NPs 
in the existing organs-on-chips are currently nascent.
Most abundantly investigated topic is the transport 
assessment of NPs in a 3D microfluidic organs-on-chips 
system. For example, a double-layered microfluidic device 
lined by an endothelial monolayer mimics a microvas-
cular layer that can be utilized to study the transloca-
tion of gold NPs conjugated with poly(lactic-co-glycolic 
acid) (PLGA) or lipid-PLGA NPs in the atherosclerosis 
model with controllable permeability (Fig.  3a) [76]. The 
translocation of NPs across the endothelium (HUVEC) 
is shown to be dependent on the microvascular perme-
ability. When the endothelial cells grown on the nanopo-
rous membrane are challenged to the proinflammatory 
cytokine involved in the pathogenesis of atherosclero-
sis, microvascular permeability increases, which results 
in the increased translocation of the lipid-polymer NPs 
through the endothelial layer. This approach improves 
the physiological relevance by recapitulating the tissue–
tissue interface of a local vascular microenvironment 
under in vivo relevant shear flow, which makes a consid-
erable difference compared to the conventional microflu-
idic approach.
NPs also have been applied in the microfluidic 3D 
tumor model (“Tumor microenvironment-on-chip”) 
reconstituting the breast cancer microenvironment 
surrounded by the lymphatic and capillary microves-
sels (Fig.  3b) [77]. This model has four segregated 
microchannels separated by the nanoporous membrane, 
where each channel mimics capillary, lymph, and tumor 
compartments. In the upper microchannel, capillary 
human microvascular endothelial cells (HMVEC) are 
cultured on a porous membrane. In the bottom layer, 
there are three microchannels, in which the center chan-
nel simulates the solid tumor by employing the breast 
cancer cell line (MCF-7) in collagen matrix. Beside the 
center channel, there are two side channels mimicking 
the lymphatic vessels. This study reveals that the trans-
port of NPs is dependent on the diameter of NPs (best 
in 100 nm), cut-off size (best in 400 nm), ECM concen-
trations (best in 6 mg/mL), and interstitial fluid pressure 
(best in 20 mmHg).
Finally, human lung-on-a-chip microfluidic device 
recapitulating the breathing motion is used to assess the 
transcytosis of NPs and their interaction with the human 
lung cells [65]. This microphysiological system has two 
juxtaposed parallel microchannels separated by a porous 
membrane coated with ECM (collagen or fibronec-
tin) and lined by the human alveolar epithelial cells and 
capillary endothelial cells on each side. Besides the cell 
microchannels, there are two hollow vacuum chambers 
connected to the computer-controlled pneumatic system 
to exert cyclic rhythmical deformations. This repeated 
stretching emulates the breathing motions in the alve-
olar-capillary tissue interface, by which the transport of 
silica NPs (12  nm in diameter) or carboxylated Cd/Se 
quantum dots (16 nm in diameter) from the alveolar side 
(i.e. upper microchannel) to the capillary side (i.e. lower 
microchannel) is significantly enhanced compared to the 
static control. Transcytosed NPs considerably increase 
the proinflammatory responses of epithelial tissue and 
the intracellular level of reactive oxygen species (ROS) on 
the alveolar epithelium. A notable discovery here is that 
the absence of mechanical physical motions in the cul-
ture system (e.g. static Transwell culture) does not induce 
any detectable levels of cellular responses such as inflam-
matory responses or ROS generation in response to the 
treatment of NPs, suggesting that the assessment of the 
safety and efficacy of NPs and their conjugates should be 
potentially performed under physiological organ-specific 
dynamics.
3  Future perspectives
The convergence of nanotechnology and bioengineering 
is one of the promising pathways for pharmaceutical and 
clinical applications. The validation of in  vivo function-
ality and safety of NPs, however, remains as a key miss-
ing piece, which restricts the applications of NPs for the 
smart drug delivery or the therapeutic treatment to the 
patients. Furthermore, a more sophisticated integration 
of multiple NP-based sensing modules that can detect, 
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amplify, and process the cellular secretomes during cell–
cell or cell-microbe interactions is a critical unmet need. 
To surmount these challenges, organs-on-chips technol-
ogy can be contemplated as an integrative platform not 
only to investigate the functionality of NPs on the specific 
organ/disease model (Fig.  3) but also to analyze diverse 
cellular and molecular signals in situ during the biologi-
cal (e.g. host-microbe crosstalks) or physical perturba-
tions (e.g. peristalsis-like deformations in the gut) by 
sequentially interconnecting the sensing and screening 
units (Fig. 4).
For example, a human gut-on-a-chip device [66, 68, 
78] employing intestinal villi colonized by gut microbi-
ome demonstrates complex host-microbiome interac-
tions that can modulate epithelial differentiation and 
immune modulation (e.g. balance of helper vs. regula-
tory T lymphocytes) (Fig.  4a) [78]. During the complex 
host-microbe interactions, gut microbiome, intestinal 
epithelium, and resident immune components produce 
various molecular secretomes such as short-chain fatty 
acids (SCFA) [79], cytokines and chemokines [80], and 
antimicrobial peptides [81] under homeostatic condi-
tion. When this microenvironment is challenged by the 
factors that can induce inflammatory responses such 
as dysbiosis [82], susceptible genetic background of the 
host [83], pathogenic infection [84], or ingestion of toxic 
compounds [85], intestinal homeostasis is immediately 
compromised resulting in the switch-on of inflamma-
tory signaling cascades and subsequent secretion of pro-
inflammatory cytokines that can exacerbate the disease 
symptoms. Hence understanding the fate of those inter-
mediate compounds and their steady-state homeostatic 
level is of great importance to interrogate cellular and 
microbial signatures in situ. And obviously, this is a criti-
cal feature that cannot be easily achieved by existing ani-
mal, 2D in vitro, and 3D static organoid models.
We anticipate sequential integration of NP-guided 
“Detection units” that can rapidly and accurately quan-
titate the transient level of metabolites and secretomes 
released by the cells grown in an organ chip (Fig. 4b, c). 
Fig. 3 Human organs‑on‑chips for assessing the transport efficiency of NPs. a A schematic of the normal capillaries surrounding the vessel wall and 
the atherosclerosis microenvironment with surrounding permeable vasculature (left). A schematic of a microfluidic device (right) in which the NPs 
are introduced into the upper microchannel, and the translocation of NPs is measured in the lower microchannel. Reproduced with permission [76]. 
Copyright 2014, National Academy of Sciences. USA. b Schematics of the in vivo solid tumor (left), tumor microenvironment composed of capillary 
and lymphatic microvessels (middle), and the tumor microenvironment‑on‑chip (right). NPs are introduced into the capillary channel and they trans‑
port to the lymphatic vessels through the tumor channel, mimicking the permeable microvessels in atherosclerosis. Reproduced with permission 
[77]. Copyright 2014, Elsevier
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The concentration of secretomes may be instantly meas-
ured by the microfluidic SPR microarray detection unit 
that is linked to the gut-on-a-chip (Fig. 4b) [86]. In addi-
tion, we may assess the differentiation level of neural 
stem cells in the brain tissue that are communicating 
with the gut microbial metabolites (e.g. SCFAs) to dem-
onstrate physiological functions of the gut-brain axis 
[87] using the NP-based electrochemical sensing system 
with in situ monitoring (Fig. 4c) [88]. Similar approaches 
employing the sequential integration of other organs-on-
chips and NP-guided detection units will provide ample 
opportunities in diagnostics to understand the biological 
processes during the physiological reactions with spati-
otemporal resolution.
In this review article, we discussed the recent progresses 
of human organs-on-chips microphysiological system as 
an alternative model that can potentially replace exist-
ing animal and in vitro cell culture models. In the current 
stages, there are considerable shortcomings in organs-
on-chips technologies that are still challenging to provide 
the macroscopic feature of organ physics or inter-organ 
interactions. Furthermore, some features may never be 
possible to be realized on-chip, such as the demonstration 
of human behavior on-chip. However, the integration of 
nanotechnology with the organs-on-chips technology will 
provide a paradigm-shift in diagnostics and therapeutics, 
which can in part accelerate the practical advances for 
biomedical, pharmaceutical, and clinical applications.
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Fig. 4 A human organ‑on‑a‑chip microphysiological system integrated with sequential NP‑guided detection systems. a A cross‑sectional view of a 
human gut‑on‑a‑chip where complex interactions of gut microbiome, epithelium, and immune components occur. Reproduced with permission 
[21]. Copyright 2016, Elsevier. b “Detection unit 1” for the on‑line monitoring of cellular and microbial secretomes in the gold nanorod‑deposited 
microfluidic channel. Reproduced with permission [86]. Copyright 2015, American Chemical Society. c “Detection unit 2” sequentially connected to 
the “Detection unit 1” to validate the differentiation of neural stem cells mimicking the physiological interaction of gut‑brain axis using graphene 
oxide‑encapsulated gold NP‑guided electrochemical detection. Reproduced with permission [88]. Copyright 2013, Elsevier
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